# Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

> **NCT01767129** · PHASE2 · COMPLETED · sponsor: **Avanir Pharmaceuticals** · enrollment: 14 (actual)

## Conditions studied

- Dyskinesia
- Parkinson's Disease

## Interventions

- **DRUG:** AVP-923-45
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01767129
- **Lead sponsor:** Avanir Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-16
- **Primary completion:** 2015-02-05
- **Final completion:** 2015-02-05
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2022-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01767129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01767129, "Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01767129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*